Improvements in Cardiovascular Risk Management Needed for MPN
June 11th 2021Although cardiovascular health of patients with myeloproliferative neoplasms was relatively good, an estimated 11% to 22% of patients were not prescribed appropriate medications for management of comorbidities associated with thrombotic risk.
Read More